近日,南京江北新区生物医药谷企业维立志博宣布,其核心产品维利信已获欧盟委员会授予的罕见病药物资格认定,用于治疗肺外神经内分泌癌。罕见病药物,又称孤儿药。根据欧盟委员会的定义,孤儿药是指用于诊断、预防或治疗有生命危险或导致慢性衰弱疾病的药物,并且患者比例不超过欧盟人口总数的万分之五。维利信是一种靶向PD-L1与 4-1BB的双特异性抗体,是已处于单臂关键性临床阶段的靶向共刺激受体4-1BB的分子。...
Source Link近日,南京江北新区生物医药谷企业维立志博宣布,其核心产品维利信已获欧盟委员会授予的罕见病药物资格认定,用于治疗肺外神经内分泌癌。罕见病药物,又称孤儿药。根据欧盟委员会的定义,孤儿药是指用于诊断、预防或治疗有生命危险或导致慢性衰弱疾病的药物,并且患者比例不超过欧盟人口总数的万分之五。维利信是一种靶向PD-L1与 4-1BB的双特异性抗体,是已处于单臂关键性临床阶段的靶向共刺激受体4-1BB的分子。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.